基于TLR4激动剂的新型疫苗佐剂研究进展  

Advances in novel vaccine adjuvants based on TLR4 agonists

作　　者：李悄 王月鹏 周育森 寇志华 Li Qiao;Wang Yuepeng;Zhou Yusen;Kou Zhihua(Anhui Medical University Graduate School, Hefei 230032, China;State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China)

机构地区：[1]安徽医科大学研究生学院,合肥230032 [2]军事医学研究院微生物流行病研究所,病原微生物生物安全国家重点实验室,北京100071

出　　处：《中华微生物学和免疫学杂志》2019年第8期638-644,共7页Chinese Journal of Microbiology and Immunology

基　　金：病原微生物生物安全国家重点实验室基金课题(SKLPBS1416).

摘　　要：Toll样受体4(Toll-like receptor 4,TLR4)是目前研究较为深入的TLR,属于Ⅰ型跨膜蛋白,其配体包括革兰阴性菌脂多糖(lipopolysaccharide,LPS)及其衍生物单磷酰脂A(monophosphoryl lipid A,MPLA)等。TLR4激动剂或单独应用,或作为复合佐剂的主要组分,或与其他TLR激动剂联合使用,已广泛用于多种疫苗的研发,展现良好的应用前景。本文主要阐述以TLR4激动剂为基础的新型疫苗佐剂的发现、应用、特点及发展趋势,为合理选择使用佐剂和新型佐剂的研发提供参考。Toll-like receptor 4 (TLR4), a type Ⅰ transmembrane protein, has been extensively studied in the Toll-like receptor family at present. TLR4 ligands include lipopolysaccharides (LPS) present in the outer membrane of gram-negative bacteria and monophosphoryl lipid A (MPLA) which is a derivative of LPS. TLR4 agonists, alone, as a major component of compound adjuvants or in combination with other TLRs agonists, have been widely used as adjuvants in various vaccines and demonstrated great potential in vaccine development. This review addressed the discovery, application, features and prospect of novel vaccine adjuvants based on TLR4 agonists, aiming to provide reference for rational use of adjuvants and further development.

关 键 词：佐剂 免疫刺激剂 TLR4 疫苗 

分 类 号：R392-33[医药卫生—免疫学]